Physician profile
Eduardo Daniel Rosas Blum
NPI 1316133218
$26,185.62
in general payments reported to CMS, 2019-2025
18 companies · $15K in 2025
The $15K reported for 2025 was more than what 95% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2021: $165 · 2022: $185 · 2023: $677 · 2024: $9,740 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $3,437 · Travel and Lodging: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,700.00 |
| Food and Beverage | $3,437.11 |
| Travel and Lodging | $1,561.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $24,394.38 | 2022-2025 | Livmarli, Cholbam, Chenodal |
| Takeda Pharmaceuticals U.S.A., INC. | $326.32 | 2021-2025 | Eohilia, Gattex |
| Ipsen Biopharmaceuticals, INC | $254.76 | 2023-2025 | Bylvay |
| Qol Medical, LLC | $216.80 | 2024-2025 | Sucraid, Sucraid |
| Echosens North America, INC. | $195.91 | 2023 | Fibroscan |
| Genzyme Corporation | $174.52 | 2024-2025 | |
| Travere Therapeutics, INC. | $163.24 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $144.95 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $88.39 | 2023 | Linzess |
| Fresenius Kabi USA, LLC | $65.45 | 2022-2024 | Smoflipid |
| Sandoz INC. | $48.01 | 2023 | Hyrimoz |
| Alcresta Therapeutics, INC. | $42.37 | 2022-2025 | Relizorb |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.06 | 2023 | Cyltezo |
| Albireo Pharma, INC. | $17.85 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $15.44 | 2023 | Kristalose |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $14.17 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Rosas Blum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.